125I-ABY-025

N/A

Report date: 2025/11/21 17:41:06
NME

Base Information

Drug Name125I-ABY-025
Drug Alias Name125I-ABY-025
ClassificationSmall molecules > Heterocyclic drugsRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Nuclides > Iodine > 125I +[4] 
Mechanisms of ActionSingle-photon emission-computed tomography enhancersReceptor protein-tyrosine kinase erbB-2 antagonistsPositron-emission tomography enhancers
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAffibody Ab
China Registration ClassN/A

Develop Information

Active CompaniesAffibody Ab
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A